
Featured
The Prescription Paradox: How Medicare's Second Tranche of Drug Negotiations is Rewiring the Pharmaceutical Supply Chain
HHS's second tranche of Medicare drug price negotiations is silently redirecting R&D capital and accelerating PBM consolidation. Stakeholders must nav...
Read Full Story →